Concurrent combination of chemotherapeutic drugs is a promising alternative to single-agent
therapies in
cancer. In the present study,
paclitaxel and
parthenolide were loaded into mixed
micelles and tested against
taxol sensitive (A549) and resistant (A549-T24) NSCLC cell lines.
Combination chemotherapy was further evaluated by isobologram analyses and combination index calculations. Drugs were loaded into
micelles by the film casting method using PEG(2000)-DSPE and
vitamin E-TPGS.
Micelle characterization studies included the determination of particle size, encapsulation efficiency, in vitro release kinetics, as well as 1H NMR analysis. The in vitro release of both drugs was slower from the mixed
micelles, which maintained an encapsulation efficiency >95% and chemical stability over a storage period of 45 days. The IC50 of
paclitaxel and
parthenolide determined by MTT assay were 108.6nM and 21μM, respectively, while the combination had an IC50 of 64.15nM in A549 cells. In the
taxol resistant cell lines, the IC50 values of
paclitaxel and
parthenolide were 233nM and 32μM, respectively, while the combination had an IC(50) of 128nM. The efficacy of
paclitaxel and
parthenolide against both cell lines significantly increased when the drugs were coencapsulted in mixed
micelles. Mixed
micelles caused 79% cell death, which was significantly higher than the 46% cell death caused by the drugs in
solution against
taxol sensitive cell lines. In
taxol resistant cell lines, the cell death caused by mixed
micelles was 70% as compared to 45% cell death caused by un-encapsulated drugs. Co-encapsulation of
parthenolide with
paclitaxel in mixed
micelles increased the anticancer activity of
paclitaxel against resistant and sensitive
lung cancer cell lines.